



Built on nearly **five decades of experience** with a **Vision to change the trajectory of lives for a new day**, The Company creates ingenious medical solutions for select neurological and cardiac conditions.

LivaNova is a
\$1.39B* Global Medical
Technology Company

- Targeting growing market segments and unmet patient needs
- Leadership positions in Cardiopulmonary and Epilepsy
- Diverse global product portfolio and pipeline
- Improving the quality of patients' lives

Headquartered in London

3,300 Employees

Presence in more than 100 countries

Pro forma revenues by geography: **US: 53% EU: 20% Rest of World: 27%**

Rounded numbers based on full-year 2025 revenue.

The Markets We Focus On Listed on Nasdaq stock exchange as **LIVN**

** Revenue based on full-year 2025. Numbers may not add precisely due to rounding. Global Market based on full-year 2024.*

*** Proximal Hypoglossal Nerve Stimulation Therapy*

Neuromodulation

\$592.8M Revenue*
\$7B Global Market*

Creator of
VNS Therapy™
and pHGNS
Therapy**

Disease States:
Drug-resistant epilepsy
Obstructive sleep apnea
Difficult-to-treat depression

Customers:
Neurologists
Epileptologists
ENT Specialists
Psychiatrists
Neurosurgeons
Sleep Specialists

Cardiopulmonary

\$785.4M Revenue*
\$2.1B Global Market*

Market-leading
positions

Disease States:
Coronary artery disease
Congenital heart defect
Atrial fibrillation
Valvular disease

Customers:
Perfusionists
Intensivists
Cardiac Surgeons
Cardiologists
Interventional
Cardiologists



livanova.com




Featured Products

Click the products below to learn more



Epilepsy*



SenTiva™

Enhanced programming features designed to support patients while they live their lives, along with customizable treatment and therapy management.

175,000+ patients treated with VNS Therapy™ worldwide

Cardiopulmonary*



Essenz™ Perfusion System

Designed to meet the modern needs of the New Era of Perfusion

Built on a **50-year legacy** of safety and reliability



Inspire™ Oxygenator

Personalized perfusion – safe, easy, and flexible for all adult patient sizes

4+ million patients treated to date



XTRA™ Autotransfusion System

Lowers the transfusion rates during and after cardiac surgery^{1,2}

5+ million patients treated to date

Product Pipeline Targeting medical conditions with high unmet patient needs

Difficult-to-Treat Depression (DTD)

VNS Therapy shows a significant improvement in quality of life and function. May be protective against relapse and recurrence and may return patients to “a meaningful life.”

Obstructive Sleep Apnea (OSA)

FDA-approved system leverages differentiated proximal hypoglossal nerve stimulation (pHGNS) to treat moderate to severe OSA and is the first and only HGNS therapy approved without a complete concentric collapse contraindication or warning. MRI-compatible device expected to launch in 2027.

*Products not approved in all geographics. Consult your labeling. Click appropriate links to access safety information: [VNS Therapy-Epilepsy \(US\)](#); [VNS Therapy-Epilepsy \(OUS\)](#); [Essenz Perfusion System](#); [INSPIRE Oxygenator](#); [XTRA ATS](#); [VNS Therapy-Depression \(US\)](#); [VNS Therapy-Depression \(OUS\)](#) and [OSA](#). 1.Vonk et al. Intraoperative cell salvage is associated with reduced postoperative blood loss and transfusion requirements in cardiac surgery: a cohort study. Transfusion. 2013 Nov;53(11):2782-9. | 2.Côté et al. Efficacy of intraoperative cell salvage in decreasing perioperative blood transfusion rates in first-time cardiac surgery patients: a retrospective study. Can J Surg 2016 Sep;59(5):330-6. For Depression: 1. VNS Therapy shows a significant improvement in quality of life and function – Rush AJ et al. Brain Stimul. 2025;18(3):690-700. 2. May be protective against relapse and recurrence and may return patients to “a meaningful life.” – Conway CR et al. Int J Neuropsychopharmacol. 2026;29(1):pyaf080